Data Sheet 1_Assessment of Vedolizumab and UC-MSC interaction and therapeutic potential in

Anna Merlo authored a 2.8 MB document uploaded to figshare on 2026-05-21. The document describes a study investigating the therapeutic synergy between umbilical cord-derived mesenchymal stromal cells (UC-MSCs) and Vedolizumab (VDZ) for treating acute graft-versus-host disease (aGvHD). The research includes findings on cell phenotype, immunomodulatory function, and survival outcomes in an NSG mouse model.

Use Cases

• Analyze the safety profile of combined Vedolizumab and UC-MSC therapy based on the described absence of toxicity or mutual inhibition.
• Study immunophenotype stability under inflammatory conditions based on the described maintenance of UC-MSC phenotype with Vedolizumab.
• Evaluate therapeutic dosing and timing strategies based on the described critical importance of administration windows and schedules.
• Investigate gut-specific lymphocyte trafficking blockade based on the described mechanism of Vedolizumab as an α4β7 integrin antagonist.

Strengths

• The document is licensed under CC-BY-4.0, allowing for open sharing and adaptation.
• The description provides specific biological findings, such as low α4β7 expression and unaltered IDO expression.

Limitations

• The dataset is a 2.8 MB DOCX file; its internal structure, column definitions, and row count are unknown.
• The data appears to be a single research document, not a structured dataset suitable for direct computational analysis.
• Freshness should be verified; the last update date is 2026-05-21.

Provenance

Source

Anna Merlo via figshare

Collection Method

Likely contains experimental results from a laboratory study.

Freshness

Last updated 2026-05-21 05:42:31